Novanta Inc (NASDAQ:NOVT) has earned an average broker rating score of 2.00 (Buy) from the two analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and one has assigned a strong buy rating to the company.
Brokerages have set a 12 month consensus price target of $81.00 for the company and are predicting that the company will post $0.49 EPS for the current quarter, according to Zacks. Zacks has also given Novanta an industry rank of 209 out of 255 based on the ratings given to its competitors.
A number of research firms have recently weighed in on NOVT. Zacks Investment Research upgraded Novanta from a “hold” rating to a “buy” rating and set a $82.00 target price for the company in a research report on Wednesday, February 6th. BidaskClub upgraded Novanta from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 23rd. Finally, Robert W. Baird boosted their target price on Novanta from $61.00 to $81.00 and gave the stock a “neutral” rating in a research report on Thursday, February 28th.
Novanta (NASDAQ:NOVT) last issued its quarterly earnings data on Wednesday, February 27th. The technology company reported $0.56 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.04. Novanta had a return on equity of 19.48% and a net margin of 7.99%. The firm had revenue of $156.20 million during the quarter, compared to the consensus estimate of $154.51 million. During the same quarter in the previous year, the company posted $0.44 EPS. The business’s revenue for the quarter was up 6.3% compared to the same quarter last year. As a group, research analysts predict that Novanta will post 2.35 EPS for the current fiscal year.
In other news, CAO Peter L. Chang sold 5,000 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $81.14, for a total transaction of $405,700.00. Following the completion of the sale, the chief accounting officer now owns 24,760 shares in the company, valued at $2,009,026.40. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 6.70% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. Bank of Montreal Can raised its position in shares of Novanta by 106.3% during the fourth quarter. Bank of Montreal Can now owns 462 shares of the technology company’s stock worth $29,000 after acquiring an additional 238 shares during the last quarter. Thrivent Financial for Lutherans increased its holdings in Novanta by 0.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 73,373 shares of the technology company’s stock valued at $4,623,000 after purchasing an additional 269 shares during the last quarter. Sapphire Star Partners LP increased its holdings in Novanta by 2.2% in the fourth quarter. Sapphire Star Partners LP now owns 16,711 shares of the technology company’s stock valued at $1,052,000 after purchasing an additional 362 shares during the last quarter. Strs Ohio bought a new stake in Novanta in the fourth quarter valued at about $31,000. Finally, Bank of America Corp DE increased its holdings in Novanta by 0.8% in the fourth quarter. Bank of America Corp DE now owns 120,776 shares of the technology company’s stock valued at $7,610,000 after purchasing an additional 996 shares during the last quarter. Institutional investors own 85.95% of the company’s stock.
Novanta Company Profile
Novanta Inc, together with its subsidiaries, designs, manufactures, markets, and sells photonics, vision, and precision motion components and sub-systems to original equipment manufacturers in the medical and industrial markets worldwide. The company's Photonics segment offers photonics-based solutions, including laser scanning and laser beam delivery, CO2 laser, continuous wave and ultrafast laser, and optical light engine products for photonics-based applications, such as industrial material processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.